PURE Bioscience, Inc. Q3 2026 Financial Report: Key Investor Insights
Executive Summary
PURE Bioscience, Inc. has released its Form 10-Q for the quarter ended April 30, 2026, providing a comprehensive update on its financial position, operational results, and ongoing challenges. This report contains critical information for shareholders, including continued operational losses, liquidity concerns, and recent equity transactions that may materially impact share value.
Key Financial Highlights
- Stockholders’ Deficiency: As of April 30, 2026, PURE Bioscience reported a stockholders’ deficiency of \$5,839,000. This negative equity position is a significant indicator of financial distress and could be price sensitive.
- Net Loss: The company recorded a net loss of \$1,873,000 for the nine months ended April 30, 2026, continuing its history of recurring losses.
- Cash Position: PURE Bioscience ended the quarter with cash and cash equivalents of \$983,000, down from \$1,058,000 in July 2025. This indicates limited liquidity and raises substantial doubt about the company’s ability to continue as a going concern.
- Accumulated Deficit: The accumulated deficit increased to \$140,867,000 as of April 30, 2026, up from \$138,994,000 as of July 31, 2025.
- Total Assets and Liabilities: Total assets at April 30, 2026 were \$983,000 (primarily cash), while total liabilities and stockholders’ equity matched at \$983,000, reflecting the negative equity position.
- Shares Outstanding: The company’s shares outstanding increased to 130,017,569 as of April 30, 2026, up from 111,886,473 in July 2025, primarily due to private placements.
- Equity Transactions: During the quarter, PURE Bioscience issued 18,131,096 shares of common stock in a private placement, raising net proceeds of \$1,003,000. This resulted in dilution for existing shareholders.
- Additional Paid-In Capital: Increased to \$133,727,000 from \$132,759,000 in July 2025, reflecting new equity funding.
Liquidity and Going Concern Warning
Management has stated there is substantial doubt about the company’s ability to continue as a going concern due to recurring losses, negative equity, and limited cash. The company will need to raise additional funds through equity or debt offerings to sustain operations. If additional funding is not secured, PURE Bioscience may not be able to continue its business, which could have a material adverse effect on share value.
The company has also warned that any further equity issuances would likely result in significant dilution to existing shareholders. Debt financing, if pursued, may impose restrictive covenants and increase cash payment obligations, further impacting operational flexibility.
Operational Updates and Shareholder Risks
- Continued Business Losses: PURE Bioscience has not generated positive cash flow from operations and continues to rely on external funding. Operating results for the quarter are not indicative of future quarters, and the company’s ability to generate revenue remains uncertain.
- Private Placement Dilution: The recent private placement has increased shares outstanding by over 18 million, resulting in dilution for long-term shareholders.
- Regulatory and Market Uncertainties: The company’s future capital requirements depend on regulatory approvals, partner success, and market acceptance. Any setbacks could further impact liquidity and share value.
- Non-Accelerated Filer & Smaller Reporting Company: PURE Bioscience is classified as a non-accelerated filer and a smaller reporting company, which may impact its reporting and compliance obligations.
- No Preferred Stock Outstanding: Authorized 5,000,000 shares of preferred stock with no shares issued or outstanding as of April 30, 2026.
- Common Stock Details: Authorized 200,000,000 shares of common stock, with 130,017,569 issued and outstanding as of April 30, 2026.
Share Price Sensitivity
The following items may be price sensitive for investors:
- Going Concern Warning: The explicit statement of substantial doubt about the company’s ability to continue as a going concern is a significant red flag. This warning is likely to impact investor sentiment and could result in share price volatility.
- Dilution from Private Placement: The issuance of over 18 million new shares in a private placement, resulting in dilution for existing shareholders and a relatively modest capital raise, may affect share value.
- Negative Equity Position: The continued stockholders’ deficiency and accumulated deficit signal persistent financial challenges.
- Liquidity Concerns: Limited cash reserves and ongoing losses mean the company is reliant on future fundraising, which is uncertain.
Conclusion
PURE Bioscience, Inc. remains in a precarious financial position, with continued losses, negative equity, and urgent liquidity needs. The company’s reliance on equity financings, potential for further dilution, and going concern warning are critical for shareholders and potential investors. Any inability to secure additional funding, failure to achieve positive cash flow, or adverse regulatory or market developments could materially impact the company’s share price.
Disclaimer
The information provided in this article is based on PURE Bioscience, Inc.’s Form 10-Q for the quarter ended April 30, 2026. This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisors before making any investment decisions. The company’s financial position is subject to risks that may materially affect share value, including but not limited to liquidity, dilution, and operational uncertainties.
